Full Text
Cost Effectiveness Analysis of Eribulin Mesylate (Halaven®) as a Treatment for Metastatic Breast Cancer in Mexico

Abstract

Authors

TE Jones G Tremblay U Majethia E Saunders JG Gay Molina R Gonzalez Balboa Y Huesca

Back to Volume 18, Issue 7
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×